Mediolanum International Funds Ltd Grows Stock Holdings in Insulet Co. (NASDAQ:PODD)

Mediolanum International Funds Ltd increased its position in Insulet Co. (NASDAQ:PODD - Free Report) by 32.7% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 8,890 shares of the medical instruments supplier's stock after buying an additional 2,189 shares during the period. Mediolanum International Funds Ltd's holdings in Insulet were worth $2,336,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Blue Trust Inc. raised its position in shares of Insulet by 84.1% during the third quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier's stock valued at $30,000 after buying an additional 58 shares during the last quarter. Venturi Wealth Management LLC grew its stake in Insulet by 633.3% in the third quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier's stock valued at $36,000 after acquiring an additional 133 shares during the period. TD Private Client Wealth LLC boosted its holdings in shares of Insulet by 32.6% in the third quarter. TD Private Client Wealth LLC now owns 228 shares of the medical instruments supplier's stock valued at $53,000 after buying an additional 56 shares during the period. Friedenthal Financial bought a new position in shares of Insulet during the fourth quarter worth about $57,000. Finally, Versant Capital Management Inc boosted its stake in shares of Insulet by 106.1% during the 4th quarter. Versant Capital Management Inc now owns 305 shares of the medical instruments supplier's stock worth $80,000 after buying an additional 157 shares during the last quarter.

Analyst Ratings Changes

Several equities research analysts have issued reports on PODD shares. Sanford C. Bernstein began coverage on Insulet in a report on Wednesday, November 6th. They set an "outperform" rating and a $300.00 price target for the company. Citigroup raised their price objective on shares of Insulet from $283.00 to $310.00 and gave the company a "buy" rating in a report on Wednesday, December 11th. BTIG Research upped their price target on shares of Insulet from $260.00 to $270.00 and gave the company a "buy" rating in a research report on Friday, November 8th. JPMorgan Chase & Co. upped their target price on Insulet from $280.00 to $330.00 and gave the stock an "overweight" rating in a research report on Thursday, December 12th. Finally, Canaccord Genuity Group boosted their price target on shares of Insulet from $269.00 to $304.00 and gave the stock a "buy" rating in a report on Monday, December 9th. Three investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $272.81.

Insider Buying and Selling at Insulet

In other Insulet news, CAO Lauren Budden sold 915 shares of the company's stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total value of $252,192.30. Following the transaction, the chief accounting officer now directly owns 5,733 shares in the company, valued at $1,580,129.46. This represents a 13.76 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Eric Benjamin sold 12,394 shares of Insulet stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the transaction, the executive vice president now directly owns 11,383 shares in the company, valued at approximately $3,187,240. The trade was a 52.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.47% of the stock is currently owned by insiders.

Insulet Stock Up 2.2 %

Shares of NASDAQ PODD traded up $6.22 on Wednesday, reaching $284.70. 509,899 shares of the company's stock traded hands, compared to its average volume of 536,687. The company has a market cap of $19.97 billion, a price-to-earnings ratio of 48.75, a price-to-earnings-growth ratio of 3.49 and a beta of 1.23. The business's 50 day simple moving average is $269.53 and its two-hundred day simple moving average is $239.99. Insulet Co. has a 12 month low of $160.19 and a 12 month high of $287.00. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21.

Insulet (NASDAQ:PODD - Get Free Report) last issued its earnings results on Thursday, November 7th. The medical instruments supplier reported $0.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.77 by $0.13. Insulet had a net margin of 21.22% and a return on equity of 27.98%. The company had revenue of $543.90 million for the quarter, compared to analysts' expectations of $518.50 million. During the same quarter last year, the company posted $0.71 earnings per share. As a group, equities research analysts forecast that Insulet Co. will post 3.22 EPS for the current fiscal year.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.